IL181247A - Use of 5,5-diphenyl barbituric acid in the preparation of an oral dosage form to improve the bioavailability of 5,5-diphenyl barbituric acid - Google Patents

Use of 5,5-diphenyl barbituric acid in the preparation of an oral dosage form to improve the bioavailability of 5,5-diphenyl barbituric acid

Info

Publication number
IL181247A
IL181247A IL181247A IL18124707A IL181247A IL 181247 A IL181247 A IL 181247A IL 181247 A IL181247 A IL 181247A IL 18124707 A IL18124707 A IL 18124707A IL 181247 A IL181247 A IL 181247A
Authority
IL
Israel
Prior art keywords
diphenyl
acid
barbituric acid
dosage form
sodium salt
Prior art date
Application number
IL181247A
Other languages
English (en)
Other versions
IL181247A0 (en
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of IL181247A0 publication Critical patent/IL181247A0/en
Publication of IL181247A publication Critical patent/IL181247A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL181247A 2004-08-10 2007-02-08 Use of 5,5-diphenyl barbituric acid in the preparation of an oral dosage form to improve the bioavailability of 5,5-diphenyl barbituric acid IL181247A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60032704P 2004-08-10 2004-08-10
PCT/US2005/028380 WO2006026095A2 (en) 2004-08-10 2005-08-10 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Publications (2)

Publication Number Publication Date
IL181247A0 IL181247A0 (en) 2007-07-04
IL181247A true IL181247A (en) 2012-05-31

Family

ID=34942111

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181247A IL181247A (en) 2004-08-10 2007-02-08 Use of 5,5-diphenyl barbituric acid in the preparation of an oral dosage form to improve the bioavailability of 5,5-diphenyl barbituric acid

Country Status (14)

Country Link
EP (2) EP1625848A1 (enExample)
JP (2) JP2008509914A (enExample)
KR (2) KR20070074549A (enExample)
CN (2) CN102512422A (enExample)
AT (1) ATE510541T1 (enExample)
AU (1) AU2005280419B2 (enExample)
BR (1) BRPI0513337A (enExample)
CA (1) CA2576832C (enExample)
IL (1) IL181247A (enExample)
MX (1) MX2007001655A (enExample)
NZ (1) NZ553653A (enExample)
SG (1) SG163500A1 (enExample)
WO (1) WO2006026095A2 (enExample)
ZA (1) ZA201106419B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CN100502871C (zh) 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
KR102162003B1 (ko) 2014-04-14 2020-10-06 삼성전자주식회사 무선 네트워크 연결 제어 방법 및 장치
KR101822417B1 (ko) * 2017-06-14 2018-01-29 주식회사 청도제약 인간의 체액에서 산화 스트레스를 측정하기 위한 방법
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119701A (en) * 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents
CN1896084A (zh) * 2002-01-30 2007-01-17 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
CN100502871C (zh) * 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

Also Published As

Publication number Publication date
CA2576832A1 (en) 2006-03-09
WO2006026095A2 (en) 2006-03-09
EP1781294A4 (en) 2007-12-26
SG163500A1 (en) 2010-08-30
NZ553653A (en) 2010-06-25
ATE510541T1 (de) 2011-06-15
HK1108313A1 (en) 2008-05-02
CN102512422A (zh) 2012-06-27
BRPI0513337A (pt) 2008-05-06
AU2005280419B2 (en) 2010-09-23
EP1781294B1 (en) 2011-05-25
EP1625848A1 (en) 2006-02-15
JP2013177442A (ja) 2013-09-09
MX2007001655A (es) 2007-04-23
ZA201106419B (en) 2012-05-30
IL181247A0 (en) 2007-07-04
JP2008509914A (ja) 2008-04-03
CA2576832C (en) 2013-06-11
KR20120130256A (ko) 2012-11-29
AU2005280419A1 (en) 2006-03-09
WO2006026095A3 (en) 2007-02-01
EP1781294A2 (en) 2007-05-09
KR20070074549A (ko) 2007-07-12
CN101052403A (zh) 2007-10-10

Similar Documents

Publication Publication Date Title
IL181247A (en) Use of 5,5-diphenyl barbituric acid in the preparation of an oral dosage form to improve the bioavailability of 5,5-diphenyl barbituric acid
KR100292124B1 (ko) 온단세트론을포함하는경구조성물
RU93051780A (ru) Композиции с контролируемым высвобождением, содержащие оксикодон, способ снижения ежедневных доз препаратов, содержащих оксикодон
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
AU2007267135A1 (en) Long term 24 hour intestinal administration of levodopa/carbidopa
US6200607B1 (en) Pharmaceutical composition comprising at least tyrosine and an iron compound for treating parkinson's disease or depression
RU2268727C2 (ru) Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
EP2262495B1 (en) Pharmaceutical composition comprising racetam and carnitine and process for its preparation
JP3942207B2 (ja) うつ性症状改善剤
CA2628777A1 (en) Liposomal formulation for oral administration of glutathione (reduced)
IL126199A (en) Pharmaceutical preparation for administration through the nose for preventive treatment for delayed vomiting
US3852453A (en) Method of enhancing vincamine compositions
PL200928B1 (pl) Zastosowanie kwasu α-liponowego lub jego pochodnych do wytwarzania leku do zapobiegania albo leczenia migreny
JP2001508769A (ja) アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物
SA97180188B1 (ar) تركيب وطريقة تحضير الكاربابنيم كمضاد حيوي
US7338955B1 (en) Medicament for treatment of neuropathies
EP1663247B1 (en) Use of oxcarbazepine for the improvement of sleep in patients suffering from chronic pain
JPWO2022107125A5 (enExample)
EP1676580A1 (en) Glycyrrhizin high-concentration preparation
EP0245954B1 (en) Use of etodolac for lowering uric acid blood levels
JP3125083B2 (ja) Ｔｎｆ過剰産生抑制剤
US20040138207A1 (en) Antitumor agents
JPH01163123A (ja) ビンクリスチン含有物
JP2010265186A (ja) 貧血予防用組成物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees